Substituted pyridinecarboxamides for the treatment of cancer

Details Substituted pyridinecarboxamides for the treatment of cancer Substituted pyridinecarboxamides for the treatment of cancer

2005-09-23

2011-11-15

Wilson, James O (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C548S490000

Reexamination Certificate

active

08058445

ABSTRACT:
Selected pyridine carboxamide compounds of Formula XIare effective for treatment of diseases and other maladies or conditions involving, cancer and the like.

REFERENCES:
patent: 3226394 (1965-12-01), Schipper
patent: 3406168 (1968-10-01), Schmidt
patent: 3822277 (1974-07-01), Dufour
patent: 4321371 (1982-03-01), Parg et al.
patent: 4816485 (1989-03-01), Satzinger et al.
patent: 4857662 (1989-08-01), Satzinger et al.
patent: 5532358 (1996-07-01), Kelly
patent: 5559135 (1996-09-01), Ashton et al.
patent: 5571912 (1996-11-01), Grozinger et al.
patent: 5674876 (1997-10-01), Gilbert et al.
patent: 5770613 (1998-06-01), Gaeta et al.
patent: 6008234 (1999-12-01), Kochanny et al.
patent: 6051713 (2000-04-01), Teng et al.
patent: 6140351 (2000-10-01), Arnaiz et al.
patent: 6156766 (2000-12-01), Arita et al.
patent: 6251917 (2001-06-01), Lubisch et al.
patent: 6271237 (2001-08-01), Galemmo, Jr. et al.
patent: 6313122 (2001-11-01), Beight et al.
patent: 6313151 (2001-11-01), Beight et al.
patent: 6372759 (2002-04-01), Beight et al.
patent: 6417200 (2002-07-01), Beight et al.
patent: 6448290 (2002-09-01), Ohuchida et al.
patent: 6562827 (2003-05-01), Lubisch et al.
patent: 6593352 (2003-07-01), Weichert et al.
patent: 6605626 (2003-08-01), Beight et al.
patent: 6610704 (2003-08-01), Beight et al.
patent: 6635657 (2003-10-01), Beight et al.
patent: 6660755 (2003-12-01), Song et al.
patent: 6794397 (2004-09-01), Cai et al.
patent: 6878714 (2005-04-01), Askew et al.
patent: 7101868 (2006-09-01), Elbaum et al.
patent: 7102009 (2006-09-01), Patel et al.
patent: 7514564 (2009-04-01), Chen et al.
patent: 2003/0069250 (2003-04-01), Zhu et al.
patent: 2003/0195192 (2003-10-01), Haviv et al.
patent: 2003/0195195 (2003-10-01), Haviv et al.
patent: 2004/0063775 (2004-04-01), Momose et al.
patent: 2004/0102441 (2004-05-01), Krueger et al.
patent: 2004/0254185 (2004-12-01), Ernst et al.
patent: 2005/0032816 (2005-02-01), Ernst et al.
patent: 2005/0054654 (2005-03-01), Huth et al.
patent: 0 393 529 (1990-10-01), None
patent: 0 410 148 (1991-01-01), None
patent: 0 429 987 (1991-06-01), None
patent: 0 393 529 (1993-06-01), None
patent: 0 947 500 (1999-10-01), None
patent: 1219609 (2002-07-01), None
patent: 2 168 227 (1973-08-01), None
patent: P2000 256358 (2000-09-01), None
patent: WO 96/41795 (1996-12-01), None
patent: WO 97/30035 (1997-08-01), None
patent: WO 98/24771 (1998-06-01), None
patent: WO 98/45268 (1998-10-01), None
patent: WO 99/32477 (1999-07-01), None
patent: WO 99/62885 (1999-12-01), None
patent: WO 00/02851 (2000-01-01), None
patent: WO 00/27819 (2000-05-01), None
patent: WO 00/27820 (2000-05-01), None
patent: WO 00/39111 (2000-07-01), None
patent: WO 00/39117 (2000-07-01), None
patent: WO 00/47212 (2000-08-01), None
patent: WO 01/29009 (2001-04-01), None
patent: WO 01/30745 (2001-05-01), None
patent: WO 01/55114 (2001-08-01), None
patent: WO 01/55115 (2001-08-01), None
patent: WO 01/81311 (2001-11-01), None
patent: WO 01/85671 (2001-11-01), None
patent: WO 01/85691 (2001-11-01), None
patent: WO 01/85715 (2001-11-01), None
patent: WO 02/055501 (2002-07-01), None
patent: WO 02/066470 (2002-08-01), None
patent: WO 03/068232 (2003-08-01), None
patent: WO 03/068235 (2003-08-01), None
Stein, Jay H., Ed. Internal Medicine, Mosby-Year Book, Inc., 1994, 4th ed., 699-727.
Bertino, Joseph R. and Salmon, Sydney E. Principles of Cancer Therapy, Oncology XIV, 2000, 21st ed., vol. 1, 1060-1074.
Hackam, et al. JAMA, 296(14), 2006, 1731-1732.
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, 205-213.
Konshin et al., “Synthesis and antimicrobial activity of arylamides of N-(4-pyridyl)anthranilc acid.” (1981) Chem Abstr. 97:109837.
Singh et al., “Substituted Imidazolines and their CNS Activity” (1992) Ind. J. Het. Chem. 2:129-132.
Seto et al., “Molecular Self-Assembly through Hydrogen Bonding: Supramolecular Aggregates Based on the Cyanuric Acid•Melamine Lattice.” (1993) J. Amer. Chem. Soc. 115:905-916.
Breier et al., “The role of vascular endothelial growth factor in blood vessel formation” (1996) Trends in Cell Biology 6:454-456.
Connell et al., “Patent focus on cancer chemotherapeutics. II Angiogenesis agents: Apr. 2000-Sep. 2000” (2001) Exp. Opin. Ther. Patents 11:77-114.
Bold et al., “New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis.” (2000) J. Med. Chem. 43:2310-2323.
Hennequin et al., “Design and Structure-Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitor.” (1999) J. Med. Chem. 42: 5369-5389.
Sun et al., “Design, Synthesis, and Evaluations of substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, PDGF Receptor Tyrosine Kinases.” (1999) J. Med. Chem. 42: 5120-5130.
Proudfoot et al., “Novel Non-nucleoside Inhibitors or HIV-1 Reverse Transcriptase. 3. Dipyrido[2,3-b:2′,3′-e]diazepinones”, J. Med. Chem., 38:1406-1410 (1995).
Smrckova-Voltrova et al., “Structure and Properties of Quaternized 2- and 4-aminonicotinamides”, Collect. Czech. Chem. Commun., 50:1009-1015 (1995).
Samvelyan et al., “Discussion of Some New Amino Acid Derivatives of Nicotinic Acid and Their Antisoporific Properties”, Farmakologiia I Toksikologiia, 49(3):35-37 (1986).
Hargrave et al., “Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 1. Tricyclic Pyridobenzo-0 and Dipyridodiazepinones”, J. Med. Chem., 34:2231-2241 (1991).
Adams et al., “Discovery and Development of a Non-nucleoside Reverse Transcriptase Inhibitor”, Royal Society of Chemistry, Recent Advances in the Chemistry of Anti-infective Agents, 19:282-296 (1993).
Jarzemsky, M. (Mar. 30, 2011). Amgen, Takeda's Motesanib Misses Primary Goal In Late-Stage Study. The Wall Street Journal, http://online.wsj.com/article/BT-CO-20110330-706623.html.

Affiliated with

Also associated with

Rating

Substituted pyridinecarboxamides for the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted pyridinecarboxamides for the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyridinecarboxamides for the treatment of cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4287580